BACKGROUND: Chemotherapy-induced nausea and vomiting remain common, distressing side effects of chemotherapy. It has been reported that acupressure prevents chemotherapy-induced nausea in adults, but it has not been well studied in children. METHODS: In this multicenter, prospective, randomized, single-blind, sham-controlled trial, the authors compared acute-phase nausea severity in patients ages 4 to 18 years who were receiving highly emetic chemotherapy using standard antiemetic agents combined with acupressure wrist bands, the most common type of acupressure, versus sham bands. Patients wore acupressure or sham bands continuously on each day of chemotherapy and for up to 7 days afterward. Chemotherapy-induced nausea severity in the delayed phase and chemotherapy-induced vomiting control in the acute and delayed phases also were compared. RESULTS: Of the 187 patients randomized, 165 contributed nausea severity assessments during the acute phase. Acupressure bands did not reduce the severity of chemotherapy-induced nausea in the acute phase (odds ratio [OR], 1.33; 95% confidence limits, 0.89-2.00, in which an OR <1.00 favored acupressure) or in the delayed phase (OR, 1.23; 95% CL, 0.75-2.01). Furthermore, acupressure bands did not improve daily vomiting control during the acute phase (OR, 1.57; 95% CL, 0.95-2.59) or the delayed phase (OR, 0.84; 95% CL, 0.45-1.58). No serious adverse events were reported. CONCLUSIONS: Acupressure bands were safe but did not improve chemotherapy-induced nausea or vomiting in pediatric patients who were receiving highly emetic chemotherapy. Cancer 2018; 124:1188-96.
INTRODUCTION
Despite advances in antiemetic prophylaxis, chemotherapy-induced nausea (CIN) and chemotherapy-induced vomiting (CIV) are still common and are among the most distressing side effects of chemotherapy. 1 Evaluation of CIN in pediatric patients has only recently been possible through the development and validation of pediatric, self-report measures like the Pediatric Nausea Assessment Tool (PeNAT). 2 Recent studies indicate that almost all pediatric patients receiving highly emetogenic chemotherapy (HEC) experience CIN. 3, 4 Many patients and families are interested in using nonpharmacologic therapies to control symptoms. 5 Acupuncture and acupressure are traditional Chinese medicine techniques that seek to improve health by regulating basal energy through acupoint stimulation. 6 The P6 acupoint, located on the ventral surface of the wrist, purportedly has antiemetic action. When used as an adjunct therapy, acupuncture (sterile needle insertion) at the P6 acupoint has improved CIN control in adults. 7 Acupressure is similar to acupuncture but uses pressure rather than needles. Wrist bands-the most common type of acupressure-apply pressure to the P6 acupoint. Studies of acupressure band use for CIN and CIV in adults have reported mixed results, with efficacy observed predominantly among women and patients who have a high expectation of benefit. [8] [9] [10] [11] [12] [13] To date, 2 feasibility studies have evaluated acupressure for the control of CIN and CIV in children: 1 evaluated wrist bands, and the other evaluated auricular acupressure. 14, 15 Both studies concluded that a future pediatric trial of acupressure was feasible. Neither was designed to evaluate the efficacy of acupressure in controlling CIV or CIN. Thus, the role of acupressure in reducing CIN or CIV in children is unknown.
The primary objective of the current trial was to compare CIN control in the acute phase provided by standard antiemetic agents (ondansetron or granisetron with or without dexamethasone and aprepitant) combined with acupressure bands versus sham bands in children ages 4 to 18 years who were receiving HEC. Secondary objectives were to compare CIN control in the delayed phase and to compare CIV control in the acute and delayed phases.
MATERIALS AND METHODS
This was a multicenter, international, prospective, randomized, single-blind, sham-controlled trial (National Clinical Trials [www.clinicaltrials.gov] identifier NCT01346267). It was approved by the institutional review board at each participating center. Each patient or their guardian provided informed consent. Children provided assent when they were able to do so.
Patients
English-speaking patients ages 4 to 18 years with nonrelapsed cancer and an English-speaking guardian were eligible. On initial trial activation, patients who were receiving cisplatin 50 mg/m 2 per dose were eligible. In January 2013, the eligibility criteria were expanded to include patients who were scheduled to receive 1 of the following 3 possible regimens classified as HEC 16 : 1) cisplatin 50 mg/m 2 per dose, 2) ifosfamide plus etoposide or doxorubicin, or 3) cyclophosphamide plus an anthracycline. Patients may have previously received chemotherapy other than HEC. 16 Patients who had a prior history of acupressure use or who were planning to receive antiemetic agents other than ondansetron, granisetron, dexamethasone, or aprepitant on a scheduled basis were excluded.
Definitions
A chemotherapy block was defined as a period of consecutive days when chemotherapy was administered. The acute phase began with administration of the first chemotherapy dose of a chemotherapy block and continued until 24 hours after administration of the last chemotherapy dose of the block. The delayed phase began at the end of the acute phase and continued until the first chemotherapy dose of the next chemotherapy block was received, up to a maximum of 7 days. An emetic episode was defined as a vomit or retch separated from another vomit or retch by at least 1 minute.
Study Interventions
Acupressure bands (Sea-Bands; Sea-Band International, Newport, RI) are knitted, elasticized wrist bands that apply pressure on the P6 acupoint by means of a 1-cm internal plastic stud. Sham bands differed from acupressure bands in only 1 feature: sham bands lacked the internal plastic stud. Both acupressure bands and sham bands had an external plastic stud which, in the acupressure bands, was situated directly above the internal plastic stud. The bands are intended to fit snugly enough to apply gentle, continuous pressure to the P6 acupoint. The appropriate band size (adult or pediatric) was determined for each patient. The randomization sequence was computergenerated, and patients were randomized 1:1 to acupressure bands or sham bands before the first day of chemotherapy. Randomization was stratified by chemotherapy regimen and planned antiemetic regimen during the acute phase in block sizes of 4. A study team member chose the band size, taught the patient or guardian how to place the bands, administered the first PeNAT assessment, taught the guardian how to administer the PeNAT, and instructed the patient or guardian on diary completion. This individual was not blinded to the study arm allocation of the patient. The allocation was concealed to all other health care providers, investigators, patients, and families. At the end of the study period, patients or guardians were asked which type of band (acupressure or sham) they believed the patient had been wearing.
At least 30 minutes before a patient received the first chemotherapy dose, a band (real or sham) was placed on each wrist with the external plastic stud positioned at the P6 acupoint. The patient or their guardian was asked to check the band position at least once a day. Patients were asked to wear the bands continuously throughout both the acute and delayed phases. Patients were allowed to remove the bands up to 4 times a day for up to 15 minutes at a time.
Concomitant Antiemetic Prophylaxis
On the days that patients received chemotherapy, all patients received either granisetron or ondansetron intravenously or by mouth on a scheduled basis (ie, round-theclock, not as needed). At the time of trial activation, patients without brain tumors were permitted to receive dexamethasone as a scheduled antiemetic according to per institutional/physician preference. The protocol was amended in January 2013 to permit all patients to receive scheduled dexamethasone and to permit patients aged 12 years to receive scheduled aprepitant in conjunction with dexamethasone. 17 Thus, patients received 1 of 3 possible scheduled antiemetic regimens in addition to the study intervention: ondansetron/granisetron monotherapy; ondansetron/granisetron plus dexamethasone; or, in patients aged 12 years, ondansetron/granisetron plus dexamethasone plus aprepitant. Nonscheduled (as needed) receipt of agents for breakthrough CIN and CIV was permitted and tracked.
The name, dose, and time of administration of all antiemetic agents the patient received were abstracted from the health record during the inpatient portion of the study. During the outpatient portion of the study, this information was recorded by the patient or guardian in a patient diary.
Outcomes

CIN and CIV assessment
Each patient used the PeNAT to self-assess the severity of their nausea before they received the first chemotherapy dose of the study block, at least 4 times daily (on awakening, mid-day, late afternoon, and bedtime), and any time they felt nauseated or their guardian suspected that the patient felt nauseated. PeNAT scores range from 1 (no nausea) to 4 (worst nausea).
Each patient was given a structured diary in which to record the time of each emetic episode, the PeNAT scores, and (for outpatients only) the name and time of antiemetic agents received. The frequency and duration of band removal also were noted on the diary. Families were contacted at least once during the study period by a study team member to answer any questions and to remind them to complete the diary. Patients and guardians returned the completed diaries to the participating center in person or by mail.
Adverse event reporting
Each patient's health record was reviewed for possible adverse events using the Common Terminology Criteria for Adverse Events (version 4.0; National Cancer Institute, Bethesda, MD). 18 In addition, any adverse event attributed to the bands by a patient or their guardian was recorded.
Statistical Methods
Sample size
A proportional odds model with repeated measure analysis was used to estimate the treatment effect of acupressure and to calculate sample size. A sample of 200 patients, with 100 in each study arm, was estimated to detect a cumulative odds ratio (OR) of 0.45 in nausea severity between study arms at 2-sided a level of .05 with >80% power.
Analysis
The primary study endpoint was nausea severity during the acute phase of chemotherapy, defined as the maximum PeNAT score observed during each 24-hour period. The primary analysis took a modified intent-to-treat approach, because patients were required to have contributed at least 1 PeNAT score during the acute phase to be included.
The duration of the acute phase varied with the chemotherapy regimen, according to the study design. Because of diminishing numbers of patients who received chemotherapy for longer than 3 days, data from days 4 through 7 of the acute phase were collapsed and considered to be from a single day. A generalized estimating equation (GEE) for proportional odds cumulative logit model was used to test treatment efficacy (acupressure bands vs sham bands) on repeated measures of the daily maximum PeNAT score during the acute phase. The chemotherapy regimen, antiemetic drugs actually received, treatment (acupressure bands vs sham bands), day within the acute phase, and day by treatment interaction were included in the model.
In addition, we determined the maximum PeNAT score for the entire acute phase for each patient. Generalized linear regression (a proportional odds cumulative logit model) was applied to compare the maximum nausea severity during the entire acute phase between study groups, adjusting for the effects of chemotherapy and antiemetic regimens. For the sensitivity analyses, the primary analysis was repeated in 2 subsets of patients: 1) those who provided at least 2 PeNAT scores each day of Original Article the acute phase, and 2) those who reported being compliant with application of the bands. A secondary analysis of CIN during the delayed phase was conducted using the same methods.
The daily number of emetic episodes was classified as no episodes, 1 or 2 episodes, or > 2 episodes. A GEE model with proportional odds cumulative logit for ordinal data was used to test treatment efficacy (acupressure bands vs sham bands) on repeated measures during each entire phase. The ordinal levels of emetic episodes during the entire phase between study groups were compared using a generalized linear regression model. In addition, CIV control during the entire acute or delayed phase was classified as complete (no emetic episodes and no use of breakthrough antiemetic agents), partial (1-2 emetic episodes in any 24-hour period and/or receipt of breakthrough antiemetic agents), or failed (>2 emetic episodes in any 24-hour period). The proportions of Acupressure Bands for Nausea Control/Dupuis et al Cancer March 15, 2018 patients in each of the CIV control categories were compared between study groups using a proportional odds cumulative logit model for ordinal data. This analysis accounted for the duration of the acute phase, chemotherapy agents, and antiemetic agents received.
To explore the similarities or differences of the acupressure effect in patient populations based on sex and age, an interaction with treatment (acupressure bands vs sham bands) was included in the GEE models along with the individual terms of sex or age.
Statistical analyses were performed using the SAS statistical software package (version 9.4; SAS Institute, Cary, NC). All tests of significance were 2-tailed. P values < .05 were considered statistically significant. An OR < 1.00 indicated that the acupressure group had a better outcome than the sham group, and an OR > 1.00 indicated that the acupressure group had a worse outcome than the sham group. Reasons for early withdrawal, compliance, and perception of study group allocation were compared between 2 treatment groups using the Pearson chi-square test. The length of follow-up was compared between groups using a Wilcoxon rank-sum test.
RESULTS
Patients
From May 9, 2011 to May 18, 2012, and from December 12, 2012 to May 16, 2016, 187 patients who received care in 27 institutions (Supporting Table 1 ; see online supporting information) were randomized. During the gap in enrollment, the sponsoring organization changed. At initial activation, the study was sponsored by the Children's Oncology Group with financial support through the Division of Cancer Prevention, National Cancer Institute. In 2012, the SunCoast Community Clinical Oncology Program Research Base assumed sponsorship of the study. The National Cancer Institute provided financial support throughout.
Of the 187 randomized patients, 165 entered the acute phase and contributed at least 1 PeNAT score during the acute phase, 137 participated in both the acute and delayed phases, 124 provided at least 2 PeNAT scores on each day of the acute phase, and 125 reported compliance with band application (Fig. 1) . Characteristics of the patients and their treatments are presented in Table 1 . Study groups did not differ with respect to the duration of the acute phase (P 5 .63). Table 2 ; see online supporting information). When the analysis was repeated in the subset of patients who contributed 2 PeNAT scores each day of the acute phase, once again, no difference in nausea severity was observed (acupressure bands vs sham bands: OR, 1.21; 95% CL, 0.76-1.92). A post-hoc analysis was undertaken to determine whether the time of day (morning, mid-day, afternoon, or bedtime) at which the maximum PeNAT score was recorded influenced the treatment effect in patients who reported 2 PeNAT scores on each day of the acute phase. The findings of that analysis (OR, 1.24; 95% CL, 0.78-1.97) were similar to the findings without adjusting for the time of day of PeNAT assessment (Supporting Table 3 ; see online supporting information). Most patients (92%) had nausea. Complete CIN control during the entire acute phase was uncommon (acupressure bands vs sham bands: 5% vs 11%) and did not differ between study groups (OR, 2.13; 95% CL, 0.61-7.69). This analysis was adjusted for the duration of the acute phase. Analyses of interactions of the primary efficacy variable across sex, chemotherapy, and antiemetic subgroups did not identify any subgroup of patients for which acupressure bands provided a benefit over sham bands (data not shown).
Delayed phase
In the delayed phase, 144 patients (acupressure bands group, 75; sham bands group, 69) reported at least 1 PeNAT score (Supporting Table 2 ; see online supporting information). Delayed-phase CIN severity did not differ between study groups (acupressure bands vs sham bands: OR, 1.23; 95% CL, 0.75-2.01).
Complete CIN control during the delayed phase was observed in 17% and 26% of patients in the acupressure bands and sham bands groups, respectively. The cumulative OR of having complete CIN control during the entire delayed phase was 1.56 (95% CL, 0.68-3.57) in the acupressure bands versus sham bands groups.
CIV Control
Acute phase
Most patients (78%) vomited. No difference in daily CIV control during the acute phase was observed between study groups (acupressure bands vs sham bands: OR, 1.57; 95% CL, 0.95-2.59) (Fig. 2) . There also was no difference in the proportion of patients who did not experience an emetic episode during the entire acute phase between study groups (acupressure bands vs sham bands: 41% vs 42%; OR, 0.96; 95% CL, 0.50-1.84). Similarly, there were no differences in the proportions of patients who experienced complete, partial, or failed CIV control between study groups (P 5 .33) ( Table 2) .
Delayed phase
Daily CIV control during the delayed phase did not differ between study groups (acupressure bands vs sham bands: OR, 0.84; 95% CL, 0.45-1.58). There also was no difference in the proportion of patients who never experienced an emetic episode during the entire delayed phase between study groups (acupressure bands vs sham bands: 60% vs 51%; OR, 0.53; 95% CL, 0.24-1.15) or in the proportion of patients who experienced complete, partial, or failed CIV control during the entire delayed phase (P 5 .32) ( Table 2) .
Compliance With Treatment
During the acute phase, no differences were observed between study groups with respect to the number of patients who reported taking off the bands more than was permitted (acupressure bands vs sham bands: 29% 
Perception of Study Group Allocation
Approximately one-half of patients or their guardians made a judgment regarding their study group allocation, and approximately one-third were correct. The proportions of patients and guardians who made a correct judgment regarding study group allocation did not differ between study groups (P 5 .97) (Supporting Table 4 ; see online supporting information).
Adverse Events
Six adverse events (acupressure bands group, 4 events; sham bands group, 2 events) were described as possibly or definitely related to the study intervention. Adverse events mostly commonly arose because of complaints that the bands were too tight (3 of 6). No serious adverse events possibly or definitely attributed to the bands were reported and all adverse events resolved.
DISCUSSION
In this large, randomized, single-blinded, pediatric trial, acupressure bands did not improve CIN or CIV control in children ages 4 to 18 years who were receiving HEC and ondansetron/granisetron-based antiemetic prophylaxis. Our findings remained the same whether control was defined on a daily basis or on the basis of the entire acute or delayed phase. No serious adverse effects were attributed to the use of acupressure bands or sham bands. The findings of other randomized trials evaluating acupressure bands for CIN and CIV control have been mixed. Those that reported a positive effect of acupressure bands tended to include mostly female patients who were receiving chemotherapy of variable emetogenicity and compared acupressure bands versus electrostimulation bands or usual care rather than sham bands. 8, 10, 12, 19 One of those studies noted that patients who expected acupressure bands to convey a benefit reported less severe nausea than did those who expected no benefit from the acupressure bands. 8 Thus, the benefit of acupressure bands was attributed, at least in part, to a placebo effect. We did not assess the pre-existing beliefs regarding acupressure held by our patients or their guardians. Similarly, Molassiotis et al 13 speculated that patients may benefit from wearing sham bands through either a placebo effect or a biologic effect of wrist pressure without P6 acupoint stimulation. Acupressure trials comparing acupressure bands versus sham bands that enrolled both male and female patients and adjusted for chemotherapy emetogenicity, observed no benefit with respect to vomiting or nausea control. 11, 13 Patient enrollment into our study was ended abruptly because of a change in the funding model supporting our research base. It is important to consider the impact of discontinuation of patient accrual before reaching the planned sample size of 200. Because the ORs for CIN control all favored sham bands, and considering the magnitude of the ORs and their CLs in this study, it is unlikely that a positive treatment effect of acupressure would have been observed in a larger sample size.
The strengths of this study are its size, the randomized and single-blinded design, the use of sham bands, the use of patient self-report of nausea severity using a validated tool, and confirmation of the primary analysis through sensitivity analyses. Nevertheless, the findings are limited to the population studied: children ages 4 to 18 years who were receiving multiple or single days of HEC with antiemetic prophylaxis, which included ondansetron or granisetron. The results of this study cannot be generalized to children who receive chemotherapy of lower emetogenicity, acupressure at acupoints other than P6, or to other modes of acupoint stimulation, such as electric acustimulation.
It is possible that patients who reported compliance did not apply the acupressure bands properly or wear them continuously as stipulated in the protocol. However, it is unlikely that acupressure bands would be worn more optimally in clinical practice. It is also possible that simply wearing wrist bands without an internal stud applying pressure, as in the sham group, provided an antiemetic or sham effect. In response to this concern, investigators have designed 3-arm trials to include acupressure, sham acupressure, and no bands. 8, 13 We made the pragmatic decision when designing the current trial not to include a third arm because of concerns that patients and families would decline to participate in a trial with a low probability of receiving active treatment. The finding that 92% of patients in our trial experienced nausea argues against the feasibility of including a third study arm.
Patients and guardians did not adhere completely to the desired schedule of nausea severity assessment; thus, some nausea assessments were unavailable. Although we do not believe that these missing data would have influenced our estimate of the treatment effect, more frequent nausea assessment would have improved our understanding of the extent of nausea severity and its variability within and between patients.
To our knowledge, the current study is the first pediatric trial of acupressure bands. Although acupressure bands were well tolerated, we observed no improvement in CIN or CIV control in pediatric patients who were receiving HEC and ondansetron/granisetron-based antiemetic prophylaxis. Acupressure delivered using different modalities or at sites other than P6 may merit study. Almost all of our patients had nausea, and most vomited during the acute phase. Rather than the double-agent or triple-agent prophylaxis recommended by the clinical practice guideline current at the time of this trial, 17 most patients received ondansetron or granisetron monotherapy and thus did not receive guideline-consistent antiemetic care. It is clear that CIN and CIV control in pediatric patients is suboptimal. Clinical practice guideline-consistent antiemetic prophylaxis and rigorous evaluation of novel approaches to antiemetic prophylaxis are required to provide effective supportive care.
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